- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01311739
Oral Cyanocobalamin (Eligen B12) Bioavailability Study
March 8, 2011 updated by: Emisphere Technologies, Inc.
An Open-label, Single-Dose, Parallel-Group, Randomized Study of Comparative Bioavailability of B12 After Oral Administration of B2 Formulated With an Absorption Promoter (SNAC), Oral B12 Alone and IV B12 in Healthy Male Subjects
The purpose of this study is to assess and compare the pharmacokinetics (PK) of cyanocobalamin after the oral administration of Eligen® B12 (cyanocobalamin/SNAC), oral cyanocobalamin alone (commercially-available formulation) and cyanocobalamin administered intravenously (IV) (also a commercially-available formulation) to healthy male subjects under fasting conditions.
The safety and tolerability of oral Eligen® B12 (cyanocobalamin/SNAC) versus oral cyanocobalamin alone and versus IV cyanocobalamin are also assessed.
Study Overview
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects aged 18 to 45 years.
- Signed ICF prior to any study-related procedures.
- Normal organ function including renal and hepatic function.
- Normal hematological function.
- Body weight between 60 and 100 kg and within 18 - 30 kg/m2 for body mass index (BMI).
- Normal ranges in vital signs, ECG, and laboratory tests.
- Normal ranges of serum B12, methylmalonic acid (MMA), and homocysteine.
Exclusion Criteria:
- Current use (within 14 days) of acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs) (i.e., aspirin or ibuprofen)
- Current use (within 14 days) of antibiotics, antacids, multivitamins, or nutritional supplements.
- Absolute platelet count below 100 x 109/L
- History or current diagnosis of any clinically significant disease of the liver, kidneys or GI system, or any abnormal condition that compromises the function of these systems and could result in the possibility of altered absorption, excess accumulation, or impairment of metabolism or excretion of the study product.
- History or current diagnosis of any clinically significant hematological, immunological, metabolic, cardiovascular, neurological, or GI abnormalities which that should, in the opinion of the Investigator exclude the subject from this study.
- Any other clinically significant laboratory value at Screening, which, in the opinion of the Investigator, suggested a condition that could have precluded the subject from entering this study.
- At risk of transmitting infection via blood samples e.g., producing a positive HIV test at screening or having participated in a high-risk activity for contracting HIV; producing a positive HBsAg test at screening; producing a positive hepatitis C antibody test at screening.
- Participation in a clinical research study involving a new chemical entity within 30 days of study entry.
- Significant loss or donation of blood within 56 days or plasma within 30 days prior to the initial dose in this study.
- Unsuitable for any reason to receive study product in the opinion of the Investigator.
- Alcohol consumption within the last 48 hours prior to study entry or anytime during the study.
- Positive urine alcohol test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 10 mg Eligen® B12 (Cyanocobalamin/SNAC)
A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
|
Other Names:
|
Experimental: 5 mg Eligen® B12 (Cyanocobalamin/SNAC)
A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
|
Other Names:
|
Active Comparator: 5 mg Oral Cyanocobalamin
A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
|
Other Names:
|
Active Comparator: 1 mg Intravenous Cyanocobalamin
A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state.
Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Cobalamin Pharmacokinetics (PK)
Time Frame: pre-dose to 24 hours post-dose
|
Serum cobalamin evaluated via collection and processing of blood samples from predose through 24 hours.
Pharmacokinetics to be determined by non-compartmental analysis using predose to 24 hour serum cyanocobalamin non-baseline-adjusted and baseline-adjusted concentration data.
Serum cobalamin PK parameters to include: Cmax, tmax, AUClast, AUC∞, t1/2, and Kel and bioavailability (% F) of oral formulations.
|
pre-dose to 24 hours post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects with Adverse Events as a Measure of Safety and Tolerability
Time Frame: pre-dose to 24 (end-of-study) hours postdose
|
Safety evaluated through the monitoring of medical history findings, physical examination findings, concomitant medications, vital signs (including blood pressure, respiratory rate, heart rate, and temperature), laboratory tests (hematology, serum chemistry, and urinalysis values), ECGs, AEs, and serious adverse events (SAEs).
|
pre-dose to 24 (end-of-study) hours postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sandra M. Connolly, MD, MDS Pharma Services
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion
December 7, 2022
Study Completion (Actual)
June 1, 2008
Study Registration Dates
First Submitted
March 8, 2011
First Submitted That Met QC Criteria
March 8, 2011
First Posted (Estimate)
March 9, 2011
Study Record Updates
Last Update Posted (Estimate)
March 9, 2011
Last Update Submitted That Met QC Criteria
March 8, 2011
Last Verified
March 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMIS 112-C-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Cyanocobalamin
-
Haukeland University HospitalThe Research Council of Norway; The Royal Norwegian Ministry of Health; Norwegian... and other collaboratorsCompletedMyocardial Infarction | Coronary Artery Disease | Cerebrovascular StrokeNorway
-
Universität des SaarlandesInstitute of Alternative and Sustainable Nutrition (IFANE)CompletedCobalamin DeficiencyGermany
-
University of AarhusCompleted
-
Northwell HealthStaten Island University HospitalCompletedVitamin B12 DeficiencyUnited States
-
Sykehuset Innlandet HFUniversity of Oslo; University of Bergen; Inland Norway University of Applied...Recruiting
-
Emisphere Technologies, Inc.CompletedVitamin B 12 Deficiency
-
Fundació EurecatLaboratorio Echevarne; Health Tech Bio Actives, S.L.U.RecruitingEffect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status (NORMB12)Vitamin B12 Nutritional DeficiencySpain
-
Göteborg UniversityUnknown
-
University of AarhusCompletedVitamin B12 AbsorptionDenmark
-
Georgetown UniversityCompletedEnd Stage Renal Disease | HyperhomocysteinemiaUnited States